Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

[1]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[2]  R. Fonseca,et al.  Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach , 2007, Molecular Cancer Therapeutics.

[3]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[4]  L. Escoda,et al.  Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis , 2007, Leukemia.

[5]  R. Wieser,et al.  Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion , 2007, Leukemia.

[6]  L. Kmet,et al.  Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial. , 2006 .

[7]  Serge Leyvraz,et al.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.

[8]  J. Bourhis,et al.  Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.

[9]  M. Baccarani,et al.  Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Bataille,et al.  Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. , 2006, Blood.

[11]  G. Ahmann,et al.  Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. , 2005, Blood.

[12]  S. Trudel,et al.  Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Coiffier,et al.  Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02). , 2004 .

[14]  F. Mandelli,et al.  Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. , 2004, Blood.

[15]  P. L. Bergsagel,et al.  Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. , 2004, Blood.

[16]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[17]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[18]  F. Zhan,et al.  A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. , 2003, Blood.

[19]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[20]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[21]  P. L. Bergsagel,et al.  Chromosome translocations in multiple myeloma , 2001, Oncogene.

[22]  L. Baldini,et al.  Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) , 2001, British journal of haematology.

[23]  R. Bataille,et al.  Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.

[24]  R. Bataille,et al.  High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization , 1999, Genes, chromosomes & cancer.

[25]  R. Bataille,et al.  High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. , 1998, Cancer research.

[26]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.

[27]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[28]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[29]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .